| [1] |
吴世凯,宋三泰.乳腺癌患者绝经界定标准的再认识[J].癌症进展杂志,2007;5(5):409-410.
|
| [2] |
宋三泰,吴世凯.芳香化酶抑制剂治疗乳腺癌应注意的几个问题[J].肿瘤研究与临床,2005,7(6):361-363.
|
| [3] |
Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors [J]. Ann Oncol,2008,19(1):16-27.
|
| [4] |
Ortmann O, Cufer T, Dixon JM, et al. Adjuvant endocrine therapy for perimenopausal women with early breast cancer[J]. Breast,2009,18(1):2-7.
|
| [5] |
Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial[J]. Lancet,2005,366(9484):455-462.
|
| [6] |
Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial [J].Lancet,2002,359(9344):2131-2139.
|
| [7] |
Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer[J]. N Engl J Med,2004,350(11):1081-1092.
|
| [8] |
Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer[J]. N Engl J Med,2005,353(26):2747-2757.
|
| [9] |
Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial[J]. J Clin Oncol,2005,23(22):5138-5147.
|
| [10] |
Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17[J]. J Natl Cancer Inst, 2005,97(17):1262-1271.
|
| [11] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. [2011-03-10].http:/ /www.nccn.org/default.htm
|
| [12] |
Gracia CR, Sammel MD, Freeman EW, et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition[J]. Menopause,2005,12(2):128-135.
|
| [13] |
Anderson RA, Themmen AP, Al-Qahtani A, et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer [J]. Hum Reprod,2006,21(10):2583-2592.
|
| [14] |
Lutchman Singh K, Muttukrishna S, Stein RC, et al. Predictors of ovarian reserve in young women with breast cancer[[J]. Br J Cancer,2007,96(12):1808-1816.
|
| [15] |
石洁,张云山.抗苗勒管激素、抑制素B 及超声预测卵巢储备功能[J].国际生殖健康/计划生育杂志,2009,28(2):96-98.
|
| [16] |
Fanchin R, Schonäuer LM,Righini C, et al. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3 [J]. Hum Reprod,2003,18(2):323-327.
|
| [17] |
Ficicioglu C, Kutlu T, Baglam E, et al. Early follicular antimullerian hormone as an indicator of ovarian reserve [J].Fertil Steril,2006,85(3):592-596.
|
| [18] |
La Marca A, Stabile G, Artenisio AC, et al. Serum anti-Mullerian hormone throughout the human menstrual cycle[J].Hum Reprod,2006,21(12):3103-3107.
|
| [19] |
Seifer DB, MacLaughlin DT, Christian BP, et al. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles [J]. Fertil Steril,2002,77(3):468-471.
|
| [20] |
Visser JA, de Jong FH, Laven JS, et al. Anti-Mullerian hormone: a new marker for ovarian function [J]. Reproduction,2006,131(1):1-9.
|
| [21] |
La Marca A, Giulini S, Tirelli A, et al. Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology [J]. Hum Reprod,2007,22(3):766-771.
|
| [22] |
Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mullerian hormone measurement in a routine IVF program [J].Hum Reprod,2008,23(6):1359-1365.
|
| [23] |
Fawzy M, Lambert A, Harrison RF, et al. Day 5 inhibin B levels in a treatment cycle are predictive of IVF outcome [J].Hum Reprod,2002,17(6):1535-1543.
|
| [24] |
Engmann L, Sladkevicius P, AgrawalR, et al. Value of ovarian stromal blood flow velocity measurement after pituitary suppression in the prediction of ovarian responsiveness and outcome of in vitro fertilization treatment [J]. Fertil Steril,1999,7l(1):22-29.
|
| [25] |
Pavlik EJ, Depriest PD, Gallion H, et al. Ovarian volume related to age[J]. Gynecol Oncol,2000,77(3):410-412.
|
| [26] |
唐军,孙洪莲,耿京,等.经阴道超声探测绝经后卵巢可及综合症的价值[J].中国妇产科临床杂志,2004,5(5):339-342.
|
| [27] |
Bines J, Oleske DM, Cobleigh MA, et al. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer [J]. J Clin Oncol,1996,14 (5):1718-1729.
|
| [28] |
Sun W,Stegmann BJ,Henne MA,et a1. A new approach to ovarian reserve, testing [J]. Fertil Steril,2008,90(6):2196-2202.
|
| [29] |
Kwee J,Elting ME,Schats R, et a1.Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization [J].Reprod Biol Endocrinol,2007,5:9.
|
| [30] |
Lutchman Singh K, Muttukrishna S, Stein RC, et al. Predictors of ovarian reserve in young women with breast cancer[J]. Br J Cancer,2007,96(12):1808-1816.
|
| [31] |
Giuseppe L, Attilio G, Edoardo DN, et al. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD) [J]. Hematology,2007,12(2):141-147.
|